EOG
41
4
GPS
52
5
KEY
51
14
TRV
48
2
NWSA
67
2
VMC
74
2
K
51
10
PPG
68
4
FIS
43
5
AAP
29
2
XRAY
28
-6
EXR
50
2
NI
53
3
PGR
72
-2
BRK.B
49
2
CME
45
-4
ALLE
48
7
ISRG
70
2
EQR
67
5
PEP
50
2
EOG
41
4
GPS
52
5
KEY
51
14
TRV
48
2
NWSA
67
2
VMC
74
2
K
51
10
PPG
68
4
FIS
43
5
AAP
29
2
XRAY
28
-6
EXR
50
2
NI
53
3
PGR
72
-2
BRK.B
49
2
CME
45
-4
ALLE
48
7
ISRG
70
2
EQR
67
5
PEP
50
2
Financhill
Back

Allogene Therapeutics 10K Form

Sell
26

ALLO
Allogene Therapeutics

Last Price:
3.07
Seasonality Move:
10.59%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALLO News And Ratings

See the #1 stock for the next 7 days that we like better than ALLO

ALLO Financial Statistics

Sales & Book Value

Annual Sales: $95K
Cash Flow: $-53.89M
Price / Cash Flow: 0
Annual Sales: $3.04
Price / Book: 0.98

Profitability

EPS (TTM): -2.12000
Net Income (TTM): $-327.27M
Gross Margin: --
Return on Equity: -54.96%
Return on Assets: -44.29%

Allogene Therapeutics Earnings Forecast

Key Allogene Therapeutics Financial Ratios

  • The Research & Development expenses have been 255,698.95% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 6 years have been positive in 3 years.

Allogene Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALLO
CUSIP: 019770
Website: allogene.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 12.38
Quick Ratio: 12.1

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALLO Technical Analysis vs Fundamental Analysis

Sell
26
Allogene Therapeutics (ALLO) is a Sell

Is Allogene Therapeutics a Buy or a Sell?